Iradimed (IRMD) CEO Sold 5,000 Shares Worth $413,216

Iradimed (IRMD) CEO Roger E. Susi executed an open-market sale of 5,000 shares for approximately $413,216 on November 3, 2025, representing a minor portion of his holdings as he still retains over 4.5 million shares. This transaction occurred as IRMD shares have risen 49% over the past year, fueled by record third-quarter revenue of $21.2 million (up 16% year-over-year) and a raised full-year sales outlook to $83 million, suggesting the insider sale is not indicative of business concerns given the company's strong performance in MRI-compatible medical devices.

Analysis

Iradimed (IRMD) CEO Roger E. Susi executed an open-market sale of 5,000 shares on November 3, 2025, valued at approximately $413,216 at a weighted average price of $82.64 per share. This transaction represents a minor divestment, accounting for roughly 1% of his indirect equity stake, with Susi retaining over 4.5 million shares post-sale. The sale size was also half of his historical median of 10,000 shares, suggesting it is not indicative of a negative shift in company outlook.

The sale occurred amidst strong company performance, with IRMD shares appreciating 49% over the past year, closing at $84.33 on November 8, 2025. This significant gain was largely propelled by record third-quarter revenue of $21.2 million, marking a 16% year-over-year increase. Adjusted earnings also rose 9% year-over-year to $0.47 per share, demonstrating solid profitability.

Management has raised its full-year sales outlook to $83 million at the midpoint, implying a 13.4% gain for 2025, driven by rising demand for its specialized MRI-compatible medical devices. Iradimed's strategy, leveraging proprietary technology and direct sales to healthcare facilities, positions it well within this growing market segment. The company's TTM revenue stands at $80.5 million with net income of $21.18 million.

Key Decisions for Investors

• Investors should view the recent insider sale as non-material given the CEO's substantial remaining equity and the transaction's small size relative to historical patterns.
• Focus on Iradimed's robust financial performance, including 16% year-over-year Q3 revenue growth and the raised full-year sales outlook of $83 million, as primary indicators of business health.
• Monitor the sustainability of demand for MRI-compatible medical devices and the company's ability to maintain its competitive advantage and direct sales efficacy in this niche market.